

## Bölüm 4

# BENİGN PROSTAT HİPERPLAZİSİNDE MEDİKAL TEDAVİ

YAZAR: M.Eflatun DENİZ

1. Giriş
2. Bekle Gör Takibi
3. Davranış ve Uygun Diyet
4. Farmakolojik Tedavi
  - A. Monoterapiler
  - B. Kombinasyon Tedavileri
5. Kaynaklar

## Kaynaklar

---

1. Netto, N.R., Jr., et al. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. *Urology*, 1999. 53: 314.
2. McConnell, J.D., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*, 2003. 349: 2387.
3. Karavitakis, M., et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. *Eur Urol*, 2019. 75: 788.
4. Andriole, G.L., et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*, 2010. 362: 1192.
5. Hsieh, T.F., et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. *PLoS One*, 2015. 10: e0119694.
6. Oelke, M., et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged  $\geq 75$  years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. *BJU International*, 2017. 119: 793.
7. Casabe, A., et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. *J Urol*, 2014. 191: 727.
8. Sebastianelli, A., et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. *Int J Urol*, 2018. 25: 196.
9. Ichihara, K., et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. *J Urol*, 2015. 193: 921.
10. Matsuo, T., et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with alpha1-adrenergic receptor blocker monotherapy: Prospective analysis of elderly men. *BMC Urol*, 2016. 16: 45.
11. Matsukawa, Y., et al. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. *Neurourol Urodyn*, 2019.
12. Kirby, R.S., et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. *Urology*, 2003. 61: 119.
13. Roehrborn, C.G., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. *J Urol*, 2008. 179: 616.
14. Barkin, J., et al. Alpha-blocker therapy can be withdrawn in the majority of men

- following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. *Eur Urol*, 2003. 44: 461.
15. Athanasopoulos, A., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. *J Urol*, 2003. 169: 2253.
  16. Roehrborn, C.G., et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart((R)) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. *BJU Int*, 2015. 116: 450.
  17. Kaplan, S.A., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *Jama*, 2006. 296: 2319.
  18. Kim, H.J., et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. *PLoS One*, 2017. 12: e0169248.
  19. Kaplan SA, Gonzalez RR, and Te AE: Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. *Eur Urol* 2007; 51: pp. 1717-1723
  20. Gacci M, Corona G, Salvi M, et al: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *Eur Urol* 2012; 61: pp. 994-1003